TipRanks
Advertisement
Advertisement
PAVmed Reports Q2 2026 Results and Operational Progress
PremiumCompany AnnouncementsPAVmed Reports Q2 2026 Results and Operational Progress
2M ago
Is PAVM a Buy, Before Earnings?
Premium
Pre-Earnings
Is PAVM a Buy, Before Earnings?
2M ago
Lucid announces Concert issued positive coverage policy for EsoGuard test
Premium
The Fly
Lucid announces Concert issued positive coverage policy for EsoGuard test
2M ago
Analyst Reaffirms Buy on PAVmed, Citing Oncology Platform Momentum and Partnerships; Price Target Maintained at $16
PremiumRatingsAnalyst Reaffirms Buy on PAVmed, Citing Oncology Platform Momentum and Partnerships; Price Target Maintained at $16
5M ago
PAVmed Earnings Call: Restructuring Done, Execution Ahead
Premium
Company Announcements
PAVmed Earnings Call: Restructuring Done, Execution Ahead
5M ago
PAVmed reports Q1 non-GAAP EPS ($1.17) vs. ($1.97) last year
Premium
The Fly
PAVmed reports Q1 non-GAAP EPS ($1.17) vs. ($1.97) last year
5M ago
PAVmed Reports 2025 Results, Strengthens Balance Sheet
PremiumCompany AnnouncementsPAVmed Reports 2025 Results, Strengthens Balance Sheet
6M ago
PAVmed Shareholders Approve Equity Issuance and Governance Changes
Premium
Company Announcements
PAVmed Shareholders Approve Equity Issuance and Governance Changes
6M ago
PAVmed Restructures Capital With New Preferred Financing
Premium
Company Announcements
PAVmed Restructures Capital With New Preferred Financing
8M ago

Trending

Name
Price
Price Change
S&P 500
―
Dow Jones
―
Nasdaq 100
―